Results 171 to 180 of about 1,730,139 (304)

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements. [PDF]

Cancer Med
Raman R, Debata S, Govindarajan T, Kumar P.   +3 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions. [PDF]

Sci Rep
Lee KR, Kang MJ, Kim MJ, Im Y, Jeong HC, Chae YJ.   +5 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Death-ision: the link between cellular resilience and cancer resistance to treatments. [PDF]

Mol Cancer
Baldassarre G, L de la Serna I, Vallette FM.   +2 more
europepmc   +1 more source

Inhibition of autophagy; an opportunity for the treatment of cancer resistance. [PDF]

Front Cell Dev Biol, 2023
Tonkin-Reeves A, Giuliani CM, Price JT.
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Editorial: Tumor Microenvironment and Resistance to Current Therapies

Frontiers in Oncology, 2019
Ahmed Lasfar, Ahmed Lasfar, Murugabaskar Balan, Karine A. Cohen-Solal, Andrew Zloza   +4 more
doaj   +1 more source

Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy. [PDF]

J Immunother Cancer
Sax A, May P, Enssle S, Soliman N, Nedelko T, Mandracci G, Stögbauer F, Joachim L, Winter C, Bassermann F, Steiger K, El Khawanky N, Poeck H, Heidegger S.   +13 more
europepmc   +1 more source